The most islet-restricted and abundantly expressed K+ channel of the human ꞵ-cell, TALK-1, regulates electrical activity and glucose-stimulated insulin secretion (GSIS) . Recently we identified a gain-of-function (GOF) mutation near the pore domain of TALK-1 (Leu114Pro) that causes Maturity-Onset Diabetes of the Young (MODY) in an autosomal dominant manner, but only in a single family. To confirm TALK-1-Leu114Pro as the mutation that causes the MODY phenotype and investigate the impact of TALK-1 GOF on glucose homeostasis, a mouse model containing the TALK-1-Leu114Pro mutation was generated. Interestingly, mice with TALK-1-Leu114Pro mutation show neonatal lethality which may be due to alterations of islet hormone secretion during neonatal development (this was observed in heterozygous TALK-1-Leu114Pro C57BL/6J and homozygous TALK-1-Leu114Pro CD-1 (ICR) mice) . We first confirmed that TALK-1-Leu114Pro mutation resulted in a GOF in β-cell whole-cell K+ currents. On the ꞵ-cell plasma membrane the resulting TALK-1-Leu114Pro hyperpolarizing current blunted glucose-stimulated Ca2+ entry and subsequent Ca2+ oscillations, whereas on the endoplasmic reticulum membrane TALK-1-Leu114Pro enhanced IP3-induced Ca2+ release. TALK-1-Leu114Pro+/- islets also showed decreased GSIS and reduced plasma insulin levels in TALK-1-Leu114Pro+/- mice when compared to controls. TALK-1-Leu114Pro+/- mice exhibit a significant impairment in glucose homeostasis which is likely due to reduced islet Ca2+ influx and GSIS. However, TALK-1 activity in other islet cell types may also contribute to glucose dyshomeostasis in TALK-1-Leu114Pro+/- mice. For example, pancreatic α-cell area and islet glucagon secretion are increased TALK-1-Leu114Pro+/- mice. Taken together, these data prove that the MODY-associated TALK-1-Leu114Pro mutation disrupts glucose homeostasis and suggests that TALK-1 is an islet-restricted target for the treatment for diabetes.

Disclosure

A. Y. Nakhe: None. P. Dadi: None. K. E. Zaborska: None. D. Jacobson: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.